Literature DB >> 28393141

Using cluster analysis of cytokines to identify patterns of inflammation in hospitalized patients with community-acquired pneumonia: a pilot study.

Timothy L Wiemken1, Robert R Kelley1, Rafael Fernandez-Botran2, William A Mattingly1, Forest W Arnold1, Stephen P Furmanek1, Marcos I Restrepo3, James D Chalmers4, Paula Peyrani1, Rodrigo Cavallazzi5, Jose Bordon6, Stefano Aliberti7, Julio A Ramirez1.   

Abstract

INTRODUCTION: Patients with severe community-acquired pneumonia (CAP) are believed to have an exaggerated inflammatory response to bacterial infection. Therapies aiming to modulate the inflammatory response have been largely unsuccessful, perhaps reflecting that CAP is a heterogeneous disorder that cannot be modulated by a single anti-inflammatory approach. We hypothesize that the host inflammatory response to pneumonia may be characterized by distinct cytokine patterns, which can be harnessed for personalized therapies.
METHODS: Here, we use hierarchical cluster analysis of cytokines to examine if patterns of inflammatory response in 13 hospitalized patients with CAP can be defined. This was a secondary data analysis of the Community-Acquired Pneumonia Inflammatory Study Group (CAPISG) database. The following cytokines were measured in plasma and sputum on the day of admission: interleukin (IL)-1β, IL-1 receptor antagonist (IL-1ra), IL-6, CXCL8 (IL-8), IL-10, IL-12p40, IL-17, interferon (IFN)γ, tumor necrosis factor (TNF)α, and CXCL10 (IP-10). Hierarchical agglomerative clustering algorithms were used to evaluate clusters of patients within plasma and sputum cytokine determinations.
RESULTS: A total of thirteen patients were included in this pilot study. Cluster analysis identified distinct inflammatory response patterns of cytokines in the plasma, sputum, and the ratio of plasma to sputum.
CONCLUSIONS: Inflammatory response patterns in plasma and sputum can be identified in hospitalized patients with CAP. Characterization of the local and systemic inflammatory response may help to better discriminate patients for enrollment into clinical trials of immunomodulatory therapies.

Entities:  

Keywords:  Cytokines; immunomodulation; inflammatory response; outcomes; pneumonia; steroids

Year:  2017        PMID: 28393141      PMCID: PMC5382869          DOI: 10.18297/jri/vol1/iss1/1/

Source DB:  PubMed          Journal:  Univ Louisville J Respir Infect


  34 in total

1.  Dexamethasone and length of hospital stay in patients with community-acquired pneumonia: a randomised, double-blind, placebo-controlled trial.

Authors:  Sabine C A Meijvis; Hans Hardeman; Hilde H F Remmelts; Rik Heijligenberg; Ger T Rijkers; Heleen van Velzen-Blad; G Paul Voorn; Ewoudt M W van de Garde; Henrik Endeman; Jan C Grutters; Willem Jan W Bos; Douwe H Biesma
Journal:  Lancet       Date:  2011-06-01       Impact factor: 79.321

2.  Understanding the potential role of statins in pneumonia and sepsis.

Authors:  Sachin Yende; Eric B Milbrandt; John A Kellum; Lan Kong; Russell L Delude; Lisa A Weissfeld; Derek C Angus
Journal:  Crit Care Med       Date:  2011-08       Impact factor: 7.598

3.  Addition of a macrolide to a beta-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia.

Authors:  José A Martínez; Juan P Horcajada; Manuel Almela; Francesc Marco; Alex Soriano; Elisa García; Maria Angeles Marco; Antoni Torres; Josep Mensa
Journal:  Clin Infect Dis       Date:  2003-01-31       Impact factor: 9.079

4.  Statins and outcomes in patients admitted to hospital with community acquired pneumonia: population based prospective cohort study.

Authors:  Sumit R Majumdar; Finlay A McAlister; Dean T Eurich; Raj S Padwal; Thomas J Marrie
Journal:  BMJ       Date:  2006-10-23

5.  Increased statin prescribing does not lower pneumonia risk.

Authors:  Linnea A Polgreen; Elizabeth A Cook; John M Brooks; Yuexin Tang; Philip M Polgreen
Journal:  Clin Infect Dis       Date:  2015-03-10       Impact factor: 9.079

6.  Recombinant tissue factor pathway inhibitor in severe community-acquired pneumonia: a randomized trial.

Authors:  Richard G Wunderink; Pierre-François Laterre; Bruno Francois; Dominique Perrotin; Antonio Artigas; Luis Otero Vidal; Suzana M Lobo; Jorge San Juan; Sung Chul Hwang; Thierry Dugernier; Steven LaRosa; Xavier Wittebole; Jean-Francois Dhainaut; Christopher Doig; Meryl H Mendelson; Christian Zwingelstein; Guoqin Su; Steven Opal
Journal:  Am J Respir Crit Care Med       Date:  2011-02-04       Impact factor: 21.405

7.  Indices of airway inflammation in induced sputum: reproducibility and validity of cell and fluid-phase measurements.

Authors:  E Pizzichini; M M Pizzichini; A Efthimiadis; S Evans; M M Morris; D Squillace; G J Gleich; J Dolovich; F E Hargreave
Journal:  Am J Respir Crit Care Med       Date:  1996-08       Impact factor: 21.405

8.  Efficacy of corticosteroids in community-acquired pneumonia: a randomized double-blinded clinical trial.

Authors:  Dominic Snijders; Johannes M A Daniels; Casper S de Graaff; Tjip S van der Werf; Wim G Boersma
Journal:  Am J Respir Crit Care Med       Date:  2010-02-04       Impact factor: 21.405

9.  Hydrocortisone and tumor necrosis factor in severe community-acquired pneumonia. A randomized controlled study.

Authors:  P Marik; P Kraus; J Sribante; I Havlik; J Lipman; D W Johnson
Journal:  Chest       Date:  1993-08       Impact factor: 9.410

10.  Influenza and COPD mortality protection as pleiotropic, dose-dependent effects of statins.

Authors:  Floyd J Frost; Hans Petersen; Kristine Tollestrup; Betty Skipper
Journal:  Chest       Date:  2007-04       Impact factor: 9.410

View more
  7 in total

1.  Performance of Machine Learning Algorithms for Predicting Adverse Outcomes in Community-Acquired Pneumonia.

Authors:  Zhixiao Xu; Kun Guo; Weiwei Chu; Jingwen Lou; Chengshui Chen
Journal:  Front Bioeng Biotechnol       Date:  2022-06-29

2.  The White Blood Cell Response in Sputum in Viral and Bacterial Pneumonias.

Authors:  Saeed Shoar; Daniel M Musher
Journal:  Open Forum Infect Dis       Date:  2022-04-12       Impact factor: 4.423

3.  Effective mathematical modelling of health passes during a pandemic.

Authors:  Stefan Hohenegger; Giacomo Cacciapaglia; Francesco Sannino
Journal:  Sci Rep       Date:  2022-04-28       Impact factor: 4.996

4.  Circulating miRNAs in sepsis-A network under attack: An in-silico prediction of the potential existence of miRNA sponges in sepsis.

Authors:  Catalin Vasilescu; Mihnea Dragomir; Mihai Tanase; Dana Giza; Raluca Purnichescu-Purtan; Meng Chen; Sai-Ching Jim Yeung; George A Calin
Journal:  PLoS One       Date:  2017-08-18       Impact factor: 3.240

5.  Inhalation of nebulized omega-3 fatty acids mitigate LPS-induced acute lung inflammation in rats: Implications for treatment of COPD and COVID-19.

Authors:  Chandrashekhar Kocherlakota; Banda Nagaraju; Narala Arjun; Akula Srinath; Kumar S D Kothapalli; J Thomas Brenna
Journal:  Prostaglandins Leukot Essent Fatty Acids       Date:  2022-03-30       Impact factor: 3.015

6.  Hypoxic human proximal tubular epithelial cells undergo ferroptosis and elicit an NLRP3 inflammasome response in CD1c+ dendritic cells.

Authors:  Helen Healy; Andrew J Kassianos; Kurt T K Giuliani; Anca Grivei; Purba Nag; Xiangju Wang; Melissa Rist; Katrina Kildey; Becker Law; Monica S Ng; Ray Wilkinson; Jacobus Ungerer; Josephine M Forbes
Journal:  Cell Death Dis       Date:  2022-08-27       Impact factor: 9.685

Review 7.  Indicators to assess physiological heat strain - Part 1: Systematic review.

Authors:  Leonidas G Ioannou; Konstantinos Mantzios; Lydia Tsoutsoubi; Sean R Notley; Petros C Dinas; Matt Brearley; Yoram Epstein; George Havenith; Michael N Sawka; Peter Bröde; Igor B Mekjavic; Glen P Kenny; Thomas E Bernard; Lars Nybo; Andreas D Flouris
Journal:  Temperature (Austin)       Date:  2022-07-31
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.